← Leaderboards
Guangrong Zheng
University Of Kentucky
$6,917,707
Attributed
$14,670,085
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2009–25$2.5M$1.9M$1.3M$625K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,670,085 · 11
By mechanism
R01$11,628,567 · 5
P20$1,340,998 · 1
R21$766,755 · 2
R56$750,640 · 2
R03$183,125 · 1
Top collaborators
- Daohong Zhou22 shared
- Marina Y Konopleva7 shared
- Weizhou Zhang7 shared
- Jennifer Hartt Elisseeff5 shared
- Jose G. Trevino5 shared
- Keiran Smalley2 shared
Most similar at University Of Kentucky
Same institution · by research overlap
- Ramesh C Gupta$9,549,313
- Linda P Dwoskin$22,762,643
Others in their field
Top investigators on “Lead”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$423,098,075
- David Heimbrook · Leidos Biomedical Research, Inc.$406,926,511
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$382,410,253
Research focus
LeadCellsIn VitroDesignCancer CellToxic EffectIn VivoTechnologyUbiquitin-Protein LigaseMediatingTissuesPreventApoptosisBlood PlateletsProteinsProtacPlayMalignant NeoplasmsBaseCancer TherapyThrombocytopeniaExhibitsApoptoticSenescence
Grant awards (37)
Proteolysis targeting chimera against nuclear receptor NR4A1 for melanoma therapy$655,441
R01 · FY2025 · CA
Proteolysis-targeting chimera against BCL-XL inhibits breast cancer metastasis$514,305
R01 · FY2025 · CA
Proteolysis targeting chimera against nuclear receptor NR4A1 for melanoma therapy$678,605
R01 · FY2024 · CA
Proteolysis-targeting chimera against BCL-XL inhibits breast cancer metastasis$486,504
R01 · FY2024 · CA
Inhibition of Bcl-xL by Targeted Degradation$480,430
R01 · FY2024 · CA · contact PI
Use of BCL-xL Proteolysis targeting chimeras to treat pancreatic cancer$515,151
R01 · FY2023 · CA · contact PI
Develop BCL-xL proteolysis targeting chimeras as safer and better senolytics$501,347
R01 · FY2023 · AG · contact PI
Proteolysis-targeting chimera against BCL-XL inhibits breast cancer metastasis$497,648
R01 · FY2023 · CA
Inhibition of Bcl-xL by Targeted Degradation$495,601
R01 · FY2023 · CA · contact PI
Inhibition of Bcl-xL by Targeted Degradation$72,810
R01 · FY2023 · CA · contact PI
Use of BCL-xL Proteolysis targeting chimeras to treat pancreatic cancer$515,151
R01 · FY2022 · CA · contact PI
Develop BCL-xL proteolysis targeting chimeras as safer and better senolytics$503,572
R01 · FY2022 · AG · contact PI
Inhibition of Bcl-xL by Targeted Degradation$495,601
R01 · FY2022 · CA · contact PI
Proteolysis-targeting chimera against BCL-XL inhibits breast cancer metastasis$493,605
R01 · FY2022 · CA
Chaperone-Mediated Protein Degradation of Bcl-xL and Bcl-2$46,984
R01 · FY2022 · CA · contact PI
Use of BCL-xL Proteolysis targeting chimeras to treat pancreatic cancer$525,664
R01 · FY2021 · CA · contact PI
Develop BCL-xL proteolysis targeting chimeras as safer and better senolytics$505,755
R01 · FY2021 · AG
Inhibition of Bcl-xL by Targeted Degradation$505,715
R01 · FY2021 · CA · contact PI
Proteolysis-targeting chimera against BCL-XL inhibits breast cancer metastasis$500,180
R01 · FY2021 · CA
Use of BCL-xL Proteolysis targeting chimeras to treat pancreatic cancer$525,664
R01 · FY2020 · CA
Inhibition of Bcl-xL by Targeted Degradation$518,840
R01 · FY2020 · CA · contact PI
Develop BCL-xL proteolysis targeting chimeras as safer and better senolytics$507,895
R01 · FY2020 · AG
Identifying Novel Senolytic Agents and Molecular Targets$378,140
R56 · FY2020 · AG · contact PI
Develop BCL-xL proteolysis targeting chimeras as safer and better senolytics$560,435
R01 · FY2019 · AG
Use of BCL-xL Proteolysis targeting chimeras to treat pancreatic cancer$525,664
R01 · FY2019 · CA
Development of Novel Tocotrienol-based Radioprotective Agents$268,199
P20 · FY2019 · GM · contact PI
NCI Clinical and Translational Exploratory/ Developmental Studies$193,042
R21 · FY2019 · CA · contact PI
Development of Novel Tocotrienol-based Radioprotective Agents$268,199
P20 · FY2018 · GM · contact PI
NCI Clinical and Translational Exploratory/ Developmental Studies$165,844
R21 · FY2018 · CA · contact PI
Development of Novel Tocotrienol-based Radioprotective Agents$268,200
P20 · FY2017 · GM · contact PI
Discovery and Target Identification of Senolytic Agents$202,668
R56 · FY2017 · AG · contact PI
Discovery and Target Identification of Senolytic Agents$169,832
R56 · FY2017 · AG · contact PI
Development of Novel Tocotrienol-based Radioprotective Agents$268,200
P20 · FY2016 · GM · contact PI
Development of Novel Tocotrienol-based Radioprotective Agents$268,200
P20 · FY2015 · GM · contact PI
Development of M5 Selective Muscarinic Antagonists$222,244
R21 · FY2012 · DA · contact PI
Development of M5 Selective Muscarinic Antagonists$185,625
R21 · FY2011 · DA · contact PI
Development of Antagonists for M5 Muscarinic Acetylcholine Receptor$183,125
R03 · FY2009 · DA · contact PI